Pharmaceuticals, Biotechnology & Life Sciences

The industry group, Pharmaceuticals, Biotechnology & Life Sciences, contains the industries:

and has the constituents:

Comparative Analysis

Income Statement

($'M) 2020 2021 $ Change % Change
Revenue 9,150.8 10,310.0 1,159.2 12.7
Less: Cost of Goods Sold -3,924.4 -4,466.7 -542.3 13.8
Gross Profit 13,075.2 14,776.7 1,701.5 13.0
Less: Operating Costs -2,509.9 -2,713.3 -203.4 8.1
Operating Profit 15,585.1 17,490.0 1,904.9 12.2
Less: Financing Costs -143.8 -166.9 -23.1 16.1
Earnings Before Tax 15,728.9 17,656.9 1,928.0 12.3
Less: Income Tax -470.2 -588.1 -117.9 25.1
Net Profit 16,199.1 18,245.0 2,045.9 12.6

Balance Sheet

($'M) 2020 2021 $ Change % Change
Current Assets 6,446.2 7,389.7 943.5 14.6
Non Current Assets 9,018.5 10,767.2 1,748.7 19.4
Assets 15,464.7 18,156.9 2,692.2 17.4
Current Liabilities 2,141.5 3,103.6 962.1 44.9
Non Current Liabilities 6,795.7 6,672.0 -123.7 -1.8
Liabilities 8,937.2 9,775.6 838.4 9.4
Equity 6,527.5 8,381.3 1,853.8 28.4

Cash Flow Statement

($'M) 2020 2021 $ Change % Change
Cash Flow from Operating Activities 2,488.3 3,621.9 1,133.6 45.6
Cash Flow from Financing Activities -642.7 -1,401.8 -759.1 118.1
Cash Flow from Investing Activities -1,366.7 -1,673.2 -306.5 22.4
Net Cash Flow 478.9 546.9 68.0 14.2
Foreign Exchange Fluctuations 14.6 31.9 17.3 118.5
Cash at the Beginning of the Period 657.8 1,151.3 493.5 75.0
Cash at the End of the Period 1,151.3 1,730.1 578.8 50.3

Ratio Analysis

Profitability

2020 2021 Change
Gross Profit Margin 142.9% 143.3% 0.4%
Operating Profit Margin 170.3% 169.6% -0.7%
Net Profit Margin 177.0% 177.0% -0.1%

Management Effectiveness

2020 2021 Change
Return on Assets 104.7% 100.5% -4.3%
Return on Equity 248.2% 217.7% -30.5%
Current Ratio 3.0 2.4 -0.6
Debt to Equity Ratio 1.4 1.2 -0.2

Valuation

2020 2021 Change  
Share Price ($) 287.00 285.19 -1.81 -0.6%
Ordinary Shares 454,048,707 455,128,517 1,079,810 0.2%
Market Capitalisation ($) 130,311,978,909 129,798,101,763 -513,877,146 -0.4%
Revenue per Share ($) 20.15 22.65 2.50 12.4%
Earnings per Share ($) 35.68 40.09 4.41 12.4%
Equity per Share ($) 14.38 18.42 4.04 28.1%
Dividends per Share ($) 1.94 2.10 0.16 8.2%
Dividend Yield 0.7% 0.7% 0.1%  
Price to Sales Ratio 14.2 12.6 -1.7 -11.6%
Price to Earnings Ratio 8.0 7.1 -0.9 -11.6%
Price to Book Ratio 20.0 15.5 -4.5 -22.4%